查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2135466

消化性潰瘍治療市場：全球市場預測，2026-2032年

Peptic Ulcer Medication Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，消化性潰瘍治療市場規模將成長至 40.6 億美元，複合年成長率為 8.29%。

主要市場統計數據
基準年 2025 23.2億美元
預計年份：2026年 24.9億美元
預測年份 2032 40.6億美元
複合年成長率 (%) 8.29%

消化性潰瘍治療藥物：執行摘要

消化性潰瘍治療是指旨在治癒胃潰瘍和十二指腸潰瘍、緩解症狀並降低復發風險的療法。在製定治療策略時，人們越來越重視潛在原因，特別是幽門螺旋桿菌病菌感染、非類固醇消炎劑(NSAID) 的使用、胃酸分泌過多以及出血和穿孔等併發症。該市場的發展受到實證診斷、合理使用抗生素、藥物依從性、安全監測以及基本藥物可近性的影響。

治療方法正朝著更安全、針對根本病因的個人化治療方向發展。

在臨床實務中，治療方法正從單純抑制症狀轉向針對病因的治療，包括抑制胃酸分泌、根除幽門螺旋桿菌感染（如已確診）、審查可能誘發潰瘍的藥物以及後續觀察潰瘍癒合和復發。此外，對於長期抑制胃酸分泌、藥物交互作用、抗生素抗藥性以及易感族群，處方用藥也較為謹慎。診斷檢測、基於指南的治療方案以及基層醫療、胃腸病學、藥房和醫院服務之間的協調護理正變得日益重要。

人工智慧有助於診斷、藥物依從性和安全性。

人工智慧 (AI) 可透過解讀內視鏡影像、優先處理異常觀察、識別有消化道出血風險的患者以及支援藥物調整流程，為消化性潰瘍的治療做出貢獻。預測工具可以幫助臨床醫生識別潛在的治療失敗或用藥依從性問題，而互動式系統可以改善用藥指導和追蹤提醒。這些應用需要具有代表性的檢驗、透明的性能指標、隱私保護和臨床醫生的監督，因為假陰性、偏差的訓練數據和不恰當的抗生素推薦都可能造成嚴重的臨床危害。

區域洞察：醫療保健服務和臨床能力影響治療結果

北美地區普遍受益於先進的診斷能力和內視鏡基礎設施，但仍需應對多重用藥、抗生素抗藥性、鴉片類藥物和抗發炎藥物暴露以及醫療服務可近性差異等問題。在拉丁美洲，由於診斷手段、藥物可近性和幽門螺旋桿菌抗藥性模式的差異，制定本地化的診療方案至關重要。歐洲擁有完善的指南體系，但面臨人口老化、合理使用抗生素以及各國報銷制度差異等挑戰。中東地區專科醫師資源匱乏，醫療服務可近性有顯著差異，且亟需可靠的診斷途徑。非洲需要加強醫療物資供應的連續性，提供價格合理的檢測，並提升識別和處理潰瘍併發症的能力。亞太地區的醫療體係高度多元化，在改善早期診斷、根除檢測、農村地區醫療服務可近性和抗藥性監測方面具有巨大潛力。

群體特定洞察：經濟和政策障礙影響治療路徑

東協市場需要一種能夠兼顧不同保險覆蓋範圍、都市區醫療服務可近性、藥品採購體係以及抗菌藥物抗藥性差異的方法。金磚國家公共部門能力、財政能力、診斷基礎設施和當地治療指南的顯著差異，要求採用適應性強的實施模式。歐盟受益於跨境監管和臨床協調，同時在報銷體系和醫療服務提供方面保持國家差異。七國集團（G7）的醫療衛生體系普遍擁有相對成熟的診斷和藥物安全監測能力，但在應對人口老化、複雜的藥物使用以及公平獲取醫療服務方面面臨挑戰。海灣合作理事會（GCC）國家有機會在控制對進口藥品的依賴和人力資源能力差異的同時，擴展專科醫療服務和標準化治療路徑。北約成員國的醫療衛生體系各不相同，除了常規潰瘍治療外，災害應變準備、基本藥物的持續供應以及可互通的臨床指南也至關重要。

國家概況：主要醫療保健系統的多元化優先事項

澳洲強調循證處方、合理使用抗生素以及確保地理位置分散的社區都能獲得醫療服務。巴西必須在公共醫療體系的覆蓋範圍與診斷、經濟負擔和專科醫生資源方面的區域差異之間取得平衡。加拿大由於地域遙遠以及老年人複雜的用藥方案，面臨就醫障礙。中國在不斷擴大診斷能力的同時，也面臨人口大規模、人口多樣性等問題，並持續關注幽門螺旋桿菌的管理和抗藥性問題。法國、德國、義大利和西班牙在其發達的歐洲醫療體系中，正努力應對人口老化、保險報銷差異以及長期抑酸治療合理應用等挑戰。印度在提高可負擔的檢測、治療依從性以及農村和公共醫療部門的可近性方面擁有巨大的潛力。日本和韓國擁有完善的醫療基礎設施，但必須解決老年族群中多重用藥、復發預防以及不斷演變的抗菌素抗藥性等問題。墨西哥在檢測和專科醫療服務方面存在區域差異。在俄羅斯，藥品供應的連續性、診斷品質以及對區域差異的考量是關鍵因素。在英國，優先考慮的是遵循指南、合理使用抗生素以及對出現危險症狀的患者及時轉診。在美國，儘管治療途徑廣泛，但仍面臨許多挑戰，包括醫療保健體系碎片化、藥物濫用、健康不平等以及日益嚴重的抗菌素抗藥性問題。

領導者的行動重點：改善診斷、安全性和連續性。

產業領導者應加強針對特定病因的治療路徑，將檢測、治療選擇、用藥依從性支持以及臨床需要時確認病原體根除等環節銜接起來。他們還應投資於抗菌藥物抗藥性監測和合理使用抗生素，並支持能夠減少給藥錯誤的製劑和包裝。與醫療保健系統合作可以擴大藥師主導的藥物評估、出院指導以及對有復發或出血風險患者的追蹤。數位化和人工智慧工具的實施應透過前瞻性檢驗、人工監督、網路安全措施和明確的課責來實現。藥物可及性策略不應僅依賴產品供應，還應關注藥物的可負擔性、農村地區的供應、基本藥物的可及性以及符合當地文化的教育。

調查方法：基於證據的市場分析

本執行摘要採用所提供的市場定義（消化性潰瘍治療），並建立了一個評估框架，重點關注已確立的臨床因素、治療途徑、醫療保健系統現狀和區域差異。評估結果應透過同行評審的臨床文獻、治療指南、監管出版物、藥物安全監測記錄、抗菌藥物抗藥性監測、醫療保健使用證據以及與合格的臨床醫生和藥劑師的結構化訪談進行驗證。在區域、群體和國家層面的比較中，已證實的證據和解釋應清晰區分，並根據診斷標準、抗藥性模式、安全性發現和可近性的變化檢驗。

結論：永續的價值取決於更好的潰瘍治療。

目前，消化性潰瘍的治療越來越依賴診斷的準確性、適當的胃酸分泌控制、有效的幽門螺旋桿菌感染管理以及可避免併發症的預防。抗藥性、醫療服務可近性、專科醫生資源和治療連續性等方面的差異意味著，成功的治療策略必須能夠適應當地的實際需求。那些能夠將臨床證據、醫療管理、藥物依從性支持、公平的醫療服務以及精心管理的數位化創新相結合的領導者，將更有能力改善治療效果，同時增強潰瘍治療的永續性和安全性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 消化性潰瘍治療市場：依藥物類型分類

  • H2受體拮抗劑
    • 西咪替丁
    • 法莫替丁
    • 尼扎替丁
    • 雷尼替丁
  • 黏膜保護劑
    • 次水楊酸鉍
    • 斯克拉爾法特
  • 質子幫浦阻斷劑
    • Esomeprazole
    • 蘭索拉唑
    • 奧美拉唑
    • 泮托拉唑
    • Rabeprazole
  • 合成前列腺素

第8章：消化性潰瘍治療藥物市場：依劑型分類

  • 膠囊
  • 注射藥物
  • 口服懸浮液
  • 藥片

第9章：消化性潰瘍治療市場：依最終用戶分類

  • 成人
  • 老年人
  • 兒童

第10章：消化性潰瘍治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章 消化性潰瘍治療市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第12章 消化性潰瘍治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 消化性潰瘍治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • Abbott Laboratories
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Bayer AG
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Lupin Limited
  • Merck & Co Inc
  • Novartis AG
  • Pfizer Inc
  • Roche Holding AG
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd
  • Takeda Pharmaceutical Company Limited
  • Zydus Lifesciences Ltd

第16章 主要專家

Product Code: MRR-961F26FD645C

The Peptic Ulcer Medication Market is projected to grow by USD 4.06 billion at a CAGR of 8.29% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.32 billion
Estimated Year [2026] USD 2.49 billion
Forecast Year [2032] USD 4.06 billion
CAGR (%) 8.29%

Peptic Ulcer Medication: Executive Summary

Peptic ulcer medication encompasses therapies used to heal gastric and duodenal ulcers, relieve symptoms, and reduce recurrence risk. Treatment decisions increasingly reflect the underlying cause-especially Helicobacter pylori infection, nonsteroidal anti-inflammatory drug exposure, acid hypersecretion, and complications such as bleeding or perforation. The market is shaped by evidence-based diagnosis, antimicrobial stewardship, medication adherence, safety monitoring, and access to essential medicines.

Treatment Is Shifting Toward Cause-Specific, Safer Care

Clinical practice is moving from symptom suppression alone toward cause-specific management that combines acid suppression, eradication of H. pylori when confirmed, review of ulcerogenic medicines, and follow-up for healing or recurrence. More cautious prescribing is also emerging around prolonged acid suppression, drug interactions, antimicrobial resistance, and vulnerable populations. Diagnostic testing, guideline-based treatment pathways, and coordinated care between primary care, gastroenterology, pharmacy, and hospital services are becoming increasingly important.

Artificial Intelligence Supports Diagnosis, Adherence, and Safety

Artificial intelligence can contribute to peptic ulcer care by helping interpret endoscopic images, prioritize abnormal findings, identify patients at risk of gastrointestinal bleeding, and support medication-reconciliation workflows. Predictive tools may also help clinicians identify likely treatment failure or nonadherence, while conversational systems can reinforce dosing instructions and follow-up reminders. These applications require representative validation, transparent performance measures, privacy safeguards, and clinician oversight because false negatives, biased training data, and inappropriate antibiotic recommendations could create material clinical harm.

Regional Insights: Access and Clinical Capacity Define Outcomes

North America generally benefits from advanced diagnostic and endoscopic capacity but continues to manage concerns related to polypharmacy, antimicrobial resistance, opioid and anti-inflammatory medicine exposure, and unequal access. Latin America faces variation in diagnostic availability, medicine affordability, and H. pylori resistance patterns, making locally informed protocols important. Europe combines strong guideline infrastructure with aging populations, antimicrobial-stewardship priorities, and differences in reimbursement across countries. The Middle East is characterized by uneven specialist capacity, substantial variation in healthcare access, and the need for reliable diagnostic pathways. Africa requires stronger supply continuity, affordable testing, and expanded capacity for recognizing and managing ulcer complications. Asia-Pacific contains highly diverse healthcare systems, with major opportunities to improve early diagnosis, eradication testing, rural access, and resistance surveillance.

Group Insights: Economic and Policy Blocs Shape Treatment Pathways

ASEAN markets require approaches that account for varied insurance coverage, urban-rural access, medicine procurement systems, and differing resistance profiles. BRICS countries span substantial differences in public-sector capacity, affordability, diagnostic infrastructure, and local treatment guidance, making adaptable implementation models valuable. The European Union benefits from cross-border regulatory and clinical collaboration while retaining national differences in reimbursement and care delivery. G7 systems typically have comparatively mature diagnostic and pharmacovigilance capabilities, but must address aging populations, complex medication use, and equitable access. GCC countries have opportunities to expand specialist services and standardized pathways while managing dependence on imported medicines and varied workforce capacity. NATO members represent diverse health systems, where preparedness, continuity of essential medicines, and interoperable clinical guidance are relevant alongside routine ulcer care.

Country Insights: Diverse Priorities Across Major Health Systems

Australia emphasizes evidence-based prescribing, antimicrobial stewardship, and access across geographically dispersed communities. Brazil must balance public-system reach with regional disparities in diagnostics, affordability, and specialist capacity. Canada faces distance-related access barriers and the needs of older adults with complex medicine regimens. China combines expanding diagnostic capability with large population diversity and continuing attention to H. pylori management and resistance. France, Germany, Italy, and Spain operate within well-developed European care environments while addressing aging, reimbursement variation, and appropriate long-term acid-suppression use. India has major opportunities to improve affordable testing, treatment adherence, and rural and public-sector access. Japan and South Korea have strong healthcare infrastructure but must manage aging-related polypharmacy, prevention of recurrence, and evolving resistance concerns. Mexico faces uneven access to testing and specialist care across regions. Russia requires attention to supply continuity, diagnostic quality, and geographic disparities. The United Kingdom prioritizes guideline adherence, antimicrobial stewardship, and timely referral for alarm symptoms. The United States combines extensive treatment availability with challenges involving care fragmentation, medication overuse, health inequities, and rising resistance concerns.

Action Priorities for Leaders: Improve Diagnosis, Safety, and Continuity

Industry leaders should strengthen cause-specific pathways that connect testing, treatment selection, adherence support, and confirmation of eradication where clinically indicated. They should invest in resistance surveillance and responsible antimicrobial use, while supporting formulations and packaging that reduce administration errors. Partnerships with health systems can expand pharmacist-led medication reviews, discharge education, and follow-up for patients at risk of recurrence or bleeding. Digital and AI-enabled tools should be introduced through prospective validation, human oversight, cybersecurity controls, and clear accountability. Access strategies should address affordability, rural delivery, essential-medicine availability, and culturally appropriate education rather than relying solely on product availability.

Research Methodology: Evidence-Led Market Synthesis

This executive summary uses the supplied market definition-peptic ulcer medication-and organizes the assessment around established clinical drivers, treatment pathways, healthcare-system conditions, and geographic variation. Insights should be validated through peer-reviewed clinical literature, treatment guidelines, regulatory communications, pharmacovigilance records, antimicrobial-resistance surveillance, healthcare utilization evidence, and structured interviews with qualified clinicians and pharmacists. Regional, group, and country comparisons should distinguish documented evidence from interpretation and should be updated as diagnostic standards, resistance patterns, safety findings, and access conditions change.

Conclusion: Durable Value Depends on Better Ulcer Care

The peptic ulcer medication landscape is increasingly defined by precision in diagnosis, responsible acid suppression, effective H. pylori management, and prevention of avoidable complications. Differences in resistance, healthcare access, specialist capacity, and medicine continuity mean that successful strategies must be locally adaptable. Leaders that combine clinical evidence, stewardship, adherence support, equitable delivery, and carefully governed digital innovation will be best positioned to improve outcomes while strengthening the sustainability and safety of ulcer care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Peptic Ulcer Medication Market, by Drug Type

  • 7.1. Introduction
  • 7.2. H2 Receptor Antagonists
    • 7.2.1. Cimetidine
    • 7.2.2. Famotidine
    • 7.2.3. Nizatidine
    • 7.2.4. Ranitidine
  • 7.3. Mucosal Protectants
    • 7.3.1. Bismuth Subsalicylate
    • 7.3.2. Sucralfate
  • 7.4. Proton Pump Inhibitors
    • 7.4.1. Esomeprazole
    • 7.4.2. Lansoprazole
    • 7.4.3. Omeprazole
    • 7.4.4. Pantoprazole
    • 7.4.5. Rabeprazole
  • 7.5. Synthetic Prostaglandins

8. Peptic Ulcer Medication Market, by Dosage Form

  • 8.1. Introduction
  • 8.2. Capsules
  • 8.3. Injectable
  • 8.4. Oral Suspension
  • 8.5. Tablets

9. Peptic Ulcer Medication Market, by End User

  • 9.1. Introduction
  • 9.2. Adult
  • 9.3. Geriatric
  • 9.4. Pediatric

10. Peptic Ulcer Medication Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacies
  • 10.3. Online Pharmacies
  • 10.4. Retail Pharmacies

11. Peptic Ulcer Medication Market, by Region

  • 11.1. Introduction
  • 11.2. Asia-Pacific
  • 11.3. North America
  • 11.4. Latin America
  • 11.5. Europe
  • 11.6. Middle East
  • 11.7. Africa

12. Peptic Ulcer Medication Market, by Group

  • 12.1. Introduction
  • 12.2. ASEAN
  • 12.3. GCC
  • 12.4. European Union
  • 12.5. BRICS
  • 12.6. G7
  • 12.7. NATO

13. Peptic Ulcer Medication Market, by Country

  • 13.1. Introduction
  • 13.2. United States
  • 13.3. Canada
  • 13.4. Mexico
  • 13.5. Brazil
  • 13.6. United Kingdom
  • 13.7. Germany
  • 13.8. France
  • 13.9. Russia
  • 13.10. Italy
  • 13.11. Spain
  • 13.12. China
  • 13.13. India
  • 13.14. Japan
  • 13.15. Australia
  • 13.16. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2025
  • 14.2. Market Concentration Analysis, 2025
    • 14.2.1. Concentration Ratio (CR)
    • 14.2.2. Herfindahl Hirschman Index (HHI)
  • 14.3. Recent Developments & Impact Analysis, 2025
  • 14.4. Product Portfolio Analysis, 2025
  • 14.5. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. Abbott Laboratories
  • 15.2. AstraZeneca PLC
  • 15.3. Aurobindo Pharma Limited
  • 15.4. Bayer AG
  • 15.5. Cipla Limited
  • 15.6. Dr. Reddy's Laboratories Ltd
  • 15.7. Eli Lilly and Company
  • 15.8. GlaxoSmithKline plc
  • 15.9. Lupin Limited
  • 15.10. Merck & Co Inc
  • 15.11. Novartis AG
  • 15.12. Pfizer Inc
  • 15.13. Roche Holding AG
  • 15.14. Sanofi S.A.
  • 15.15. Sun Pharmaceutical Industries Ltd
  • 15.16. Takeda Pharmaceutical Company Limited
  • 15.17. Zydus Lifesciences Ltd

16. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global Peptic Ulcer Medication Market, Years Considered for the Study
  • FIGURE 2. Global Peptic Ulcer Medication Market, Research Design
  • FIGURE 3. Global Peptic Ulcer Medication Market, Research Framework
  • FIGURE 4. Global Peptic Ulcer Medication Market, Data Triangulation
  • FIGURE 5. Global Peptic Ulcer Medication Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global Peptic Ulcer Medication Market Size, by Drug Type, 2025 vs 2032 (%)
  • FIGURE 7. Global Peptic Ulcer Medication Market Size, by Drug Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global Peptic Ulcer Medication Market Size, by Dosage Form, 2025 vs 2032 (%)
  • FIGURE 9. Global Peptic Ulcer Medication Market Size, by Dosage Form, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global Peptic Ulcer Medication Market Size, by End User, 2025 vs 2032 (%)
  • FIGURE 11. Global Peptic Ulcer Medication Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global Peptic Ulcer Medication Market Size, by Distribution Channel, 2025 vs 2032 (%)
  • FIGURE 13. Global Peptic Ulcer Medication Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global Peptic Ulcer Medication Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 15. Global Peptic Ulcer Medication Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global Peptic Ulcer Medication Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 17. Global Peptic Ulcer Medication Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 18. Global Peptic Ulcer Medication Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 19. Global Peptic Ulcer Medication Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global Peptic Ulcer Medication Market Segmentation & Coverage
  • TABLE 2. Global Peptic Ulcer Medication Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global Peptic Ulcer Medication Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 4. Global H2 Receptor Antagonists Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global H2 Receptor Antagonists Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global H2 Receptor Antagonists Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Cimetidine Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Cimetidine Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Cimetidine Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global Famotidine Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 11. Global Famotidine Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 12. Global Famotidine Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 13. Global Nizatidine Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 14. Global Nizatidine Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 15. Global Nizatidine Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 16. Global Ranitidine Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 17. Global Ranitidine Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 18. Global Ranitidine Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 19. Global Mucosal Protectants Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 20. Global Mucosal Protectants Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 21. Global Mucosal Protectants Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 22. Global Bismuth Subsalicylate Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 23. Global Bismuth Subsalicylate Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 24. Global Bismuth Subsalicylate Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 25. Global Sucralfate Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 26. Global Sucralfate Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 27. Global Sucralfate Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 28. Global Proton Pump Inhibitors Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 29. Global Proton Pump Inhibitors Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 30. Global Proton Pump Inhibitors Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 31. Global Esomeprazole Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 32. Global Esomeprazole Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 33. Global Esomeprazole Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 34. Global Lansoprazole Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 35. Global Lansoprazole Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 36. Global Lansoprazole Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 37. Global Omeprazole Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 38. Global Omeprazole Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 39. Global Omeprazole Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 40. Global Pantoprazole Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 41. Global Pantoprazole Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 42. Global Pantoprazole Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 43. Global Rabeprazole Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 44. Global Rabeprazole Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 45. Global Rabeprazole Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 46. Global Synthetic Prostaglandins Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 47. Global Synthetic Prostaglandins Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 48. Global Synthetic Prostaglandins Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 49. Global Peptic Ulcer Medication Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 50. Global Capsules Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 51. Global Capsules Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 52. Global Capsules Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 53. Global Injectable Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 54. Global Injectable Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 55. Global Injectable Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 56. Global Oral Suspension Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 57. Global Oral Suspension Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 58. Global Oral Suspension Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 59. Global Tablets Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 60. Global Tablets Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 61. Global Tablets Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 62. Global Peptic Ulcer Medication Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 63. Global Adult Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 64. Global Adult Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 65. Global Adult Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 66. Global Geriatric Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 67. Global Geriatric Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 68. Global Geriatric Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 69. Global Pediatric Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 70. Global Pediatric Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 71. Global Pediatric Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 72. Global Peptic Ulcer Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 73. Global Hospital Pharmacies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 74. Global Hospital Pharmacies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 75. Global Hospital Pharmacies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 76. Global Online Pharmacies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 77. Global Online Pharmacies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 78. Global Online Pharmacies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 79. Global Retail Pharmacies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 80. Global Retail Pharmacies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 81. Global Retail Pharmacies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 82. Global Peptic Ulcer Medication Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 83. Asia-Pacific Peptic Ulcer Medication Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 84. Asia-Pacific Peptic Ulcer Medication Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 85. Asia-Pacific Peptic Ulcer Medication Market Size, by H2 Receptor Antagonists, 2017-2032 (USD Million)
  • TABLE 86. Asia-Pacific Peptic Ulcer Medication Market Size, by Mucosal Protectants, 2017-2032 (USD Million)
  • TABLE 87. Asia-Pacific Peptic Ulcer Medication Market Size, by Proton Pump Inhibitors, 2017-2032 (USD Million)
  • TABLE 88. Asia-Pacific Peptic Ulcer Medication Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 89. Asia-Pacific Peptic Ulcer Medication Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 90. Asia-Pacific Peptic Ulcer Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 91. North America Peptic Ulcer Medication Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 92. North America Peptic Ulcer Medication Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 93. North America Peptic Ulcer Medication Market Size, by H2 Receptor Antagonists, 2017-2032 (USD Million)
  • TABLE 94. North America Peptic Ulcer Medication Market Size, by Mucosal Protectants, 2017-2032 (USD Million)
  • TABLE 95. North America Peptic Ulcer Medication Market Size, by Proton Pump Inhibitors, 2017-2032 (USD Million)
  • TABLE 96. North America Peptic Ulcer Medication Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 97. North America Peptic Ulcer Medication Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 98. North America Peptic Ulcer Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 99. Latin America Peptic Ulcer Medication Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 100. Latin America Peptic Ulcer Medication Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 101. Latin America Peptic Ulcer Medication Market Size, by H2 Receptor Antagonists, 2017-2032 (USD Million)
  • TABLE 102. Latin America Peptic Ulcer Medication Market Size, by Mucosal Protectants, 2017-2032 (USD Million)
  • TABLE 103. Latin America Peptic Ulcer Medication Market Size, by Proton Pump Inhibitors, 2017-2032 (USD Million)
  • TABLE 104. Latin America Peptic Ulcer Medication Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 105. Latin America Peptic Ulcer Medication Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 106. Latin America Peptic Ulcer Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 107. Europe Peptic Ulcer Medication Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 108. Europe Peptic Ulcer Medication Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 109. Europe Peptic Ulcer Medication Market Size, by H2 Receptor Antagonists, 2017-2032 (USD Million)
  • TABLE 110. Europe Peptic Ulcer Medication Market Size, by Mucosal Protectants, 2017-2032 (USD Million)
  • TABLE 111. Europe Peptic Ulcer Medication Market Size, by Proton Pump Inhibitors, 2017-2032 (USD Million)
  • TABLE 112. Europe Peptic Ulcer Medication Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 113. Europe Peptic Ulcer Medication Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 114. Europe Peptic Ulcer Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 115. Middle East Peptic Ulcer Medication Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 116. Middle East Peptic Ulcer Medication Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 117. Middle East Peptic Ulcer Medication Market Size, by H2 Receptor Antagonists, 2017-2032 (USD Million)
  • TABLE 118. Middle East Peptic Ulcer Medication Market Size, by Mucosal Protectants, 2017-2032 (USD Million)
  • TABLE 119. Middle East Peptic Ulcer Medication Market Size, by Proton Pump Inhibitors, 2017-2032 (USD Million)
  • TABLE 120. Middle East Peptic Ulcer Medication Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 121. Middle East Peptic Ulcer Medication Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 122. Middle East Peptic Ulcer Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 123. Africa Peptic Ulcer Medication Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 124. Africa Peptic Ulcer Medication Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 125. Africa Peptic Ulcer Medication Market Size, by H2 Receptor Antagonists, 2017-2032 (USD Million)
  • TABLE 126. Africa Peptic Ulcer Medication Market Size, by Mucosal Protectants, 2017-2032 (USD Million)
  • TABLE 127. Africa Peptic Ulcer Medication Market Size, by Proton Pump Inhibitors, 2017-2032 (USD Million)
  • TABLE 128. Africa Peptic Ulcer Medication Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 129. Africa Peptic Ulcer Medication Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 130. Africa Peptic Ulcer Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 131. Global Peptic Ulcer Medication Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 132. ASEAN Peptic Ulcer Medication Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 133. ASEAN Peptic Ulcer Medication Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 134. ASEAN Peptic Ulcer Medication Market Size, by H2 Receptor Antagonists, 2017-2032 (USD Million)
  • TABLE 135. ASEAN Peptic Ulcer Medication Market Size, by Mucosal Protectants, 2017-2032 (USD Million)
  • TABLE 136. ASEAN Peptic Ulcer Medication Market Size, by Proton Pump Inhibitors, 2017-2032 (USD Million)
  • TABLE 137. ASEAN Peptic Ulcer Medication Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 138. ASEAN Peptic Ulcer Medication Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 139. ASEAN Peptic Ulcer Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 140. GCC Peptic Ulcer Medication Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 141. GCC Peptic Ulcer Medication Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 142. GCC Peptic Ulcer Medication Market Size, by H2 Receptor Antagonists, 2017-2032 (USD Million)
  • TABLE 143. GCC Peptic Ulcer Medication Market Size, by Mucosal Protectants, 2017-2032 (USD Million)
  • TABLE 144. GCC Peptic Ulcer Medication Market Size, by Proton Pump Inhibitors, 2017-2032 (USD Million)
  • TABLE 145. GCC Peptic Ulcer Medication Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 146. GCC Peptic Ulcer Medication Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 147. GCC Peptic Ulcer Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 148. European Union Peptic Ulcer Medication Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 149. European Union Peptic Ulcer Medication Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 150. European Union Peptic Ulcer Medication Market Size, by H2 Receptor Antagonists, 2017-2032 (USD Million)
  • TABLE 151. European Union Peptic Ulcer Medication Market Size, by Mucosal Protectants, 2017-2032 (USD Million)
  • TABLE 152. European Union Peptic Ulcer Medication Market Size, by Proton Pump Inhibitors, 2017-2032 (USD Million)
  • TABLE 153. European Union Peptic Ulcer Medication Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 154. European Union Peptic Ulcer Medication Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 155. European Union Peptic Ulcer Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 156. BRICS Peptic Ulcer Medication Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 157. BRICS Peptic Ulcer Medication Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 158. BRICS Peptic Ulcer Medication Market Size, by H2 Receptor Antagonists, 2017-2032 (USD Million)
  • TABLE 159. BRICS Peptic Ulcer Medication Market Size, by Mucosal Protectants, 2017-2032 (USD Million)
  • TABLE 160. BRICS Peptic Ulcer Medication Market Size, by Proton Pump Inhibitors, 2017-2032 (USD Million)
  • TABLE 161. BRICS Peptic Ulcer Medication Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 162. BRICS Peptic Ulcer Medication Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 163. BRICS Peptic Ulcer Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 164. G7 Peptic Ulcer Medication Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 165. G7 Peptic Ulcer Medication Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 166. G7 Peptic Ulcer Medication Market Size, by H2 Receptor Antagonists, 2017-2032 (USD Million)
  • TABLE 167. G7 Peptic Ulcer Medication Market Size, by Mucosal Protectants, 2017-2032 (USD Million)
  • TABLE 168. G7 Peptic Ulcer Medication Market Size, by Proton Pump Inhibitors, 2017-2032 (USD Million)
  • TABLE 169. G7 Peptic Ulcer Medication Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 170. G7 Peptic Ulcer Medication Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 171. G7 Peptic Ulcer Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 172. NATO Peptic Ulcer Medication Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 173. NATO Peptic Ulcer Medication Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 174. NATO Peptic Ulcer Medication Market Size, by H2 Receptor Antagonists, 2017-2032 (USD Million)
  • TABLE 175. NATO Peptic Ulcer Medication Market Size, by Mucosal Protectants, 2017-2032 (USD Million)
  • TABLE 176. NATO Peptic Ulcer Medication Market Size, by Proton Pump Inhibitors, 2017-2032 (USD Million)
  • TABLE 177. NATO Peptic Ulcer Medication Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 178. NATO Peptic Ulcer Medication Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 179. NATO Peptic Ulcer Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 180. Global Peptic Ulcer Medication Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 181. United States Peptic Ulcer Medication Market Size, 2017-2032 (USD Million)
  • TABLE 182. United States Peptic Ulcer Medication Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 183. United States Peptic Ulcer Medication Market Size, by H2 Receptor Antagonists, 2017-2032 (USD Million)
  • TABLE 184. United States Peptic Ulcer Medication Market Size, by Mucosal Protectants, 2017-2032 (USD Million)
  • TABLE 185. United States Peptic Ulcer Medication Market Size, by Proton Pump Inhibitors, 2017-2032 (USD Million)
  • TABLE 186. United States Peptic Ulcer Medication Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 187. United States Peptic Ulcer Medication Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 188. United States Peptic Ulcer Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 189. Canada Peptic Ulcer Medication Market Size, 2017-2032 (USD Million)
  • TABLE 190. Canada Peptic Ulcer Medication Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 191. Canada Peptic Ulcer Medication Market Size, by H2 Receptor Antagonists, 2017-2032 (USD Million)
  • TABLE 192. Canada Peptic Ulcer Medication Market Size, by Mucosal Protectants, 2017-2032 (USD Million)
  • TABLE 193. Canada Peptic Ulcer Medication Market Size, by Proton Pump Inhibitors, 2017-2032 (USD Million)
  • TABLE 194. Canada Peptic Ulcer Medication Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 195. Canada Peptic Ulcer Medication Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 196. Canada Peptic Ulcer Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 197. Mexico Peptic Ulcer Medication Market Size, 2017-2032 (USD Million)
  • TABLE 198. Mexico Peptic Ulcer Medication Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 199. Mexico Peptic Ulcer Medication Market Size, by H2 Receptor Antagonists, 2017-2032 (USD Million)
  • TABLE 200. Mexico Peptic Ulcer Medication Market Size, by Mucosal Protectants, 2017-2032 (USD Million)
  • TABLE 201. Mexico Peptic Ulcer Medication Market Size, by Proton Pump Inhibitors, 2017-2032 (USD Million)
  • TABLE 202. Mexico Peptic Ulcer Medication Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 203. Mexico Peptic Ulcer Medication Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 204. Mexico Peptic Ulcer Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 205. Brazil Peptic Ulcer Medication Market Size, 2017-2032 (USD Million)
  • TABLE 206. Brazil Peptic Ulcer Medication Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 207. Brazil Peptic Ulcer Medication Market Size, by H2 Receptor Antagonists, 2017-2032 (USD Million)
  • TABLE 208. Brazil Peptic Ulcer Medication Market Size, by Mucosal Protectants, 2017-2032 (USD Million)
  • TABLE 209. Brazil Peptic Ulcer Medication Market Size, by Proton Pump Inhibitors, 2017-2032 (USD Million)
  • TABLE 210. Brazil Peptic Ulcer Medication Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 211. Brazil Peptic Ulcer Medication Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 212. Brazil Peptic Ulcer Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 213. United Kingdom Peptic Ulcer Medication Market Size, 2017-2032 (USD Million)
  • TABLE 214. United Kingdom Peptic Ulcer Medication Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 215. United Kingdom Peptic Ulcer Medication Market Size, by H2 Receptor Antagonists, 2017-2032 (USD Million)
  • TABLE 216. United Kingdom Peptic Ulcer Medication Market Size, by Mucosal Protectants, 2017-2032 (USD Million)
  • TABLE 217. United Kingdom Peptic Ulcer Medication Market Size, by Proton Pump Inhibitors, 2017-2032 (USD Million)
  • TABLE 218. United Kingdom Peptic Ulcer Medication Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 219. United Kingdom Peptic Ulcer Medication Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 220. United Kingdom Peptic Ulcer Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 221. Germany Peptic Ulcer Medication Market Size, 2017-2032 (USD Million)
  • TABLE 222. Germany Peptic Ulcer Medication Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 223. Germany Peptic Ulcer Medication Market Size, by H2 Receptor Antagonists, 2017-2032 (USD Million)
  • TABLE 224. Germany Peptic Ulcer Medication Market Size, by Mucosal Protectants, 2017-2032 (USD Million)
  • TABLE 225. Germany Peptic Ulcer Medication Market Size, by Proton Pump Inhibitors, 2017-2032 (USD Million)
  • TABLE 226. Germany Peptic Ulcer Medication Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 227. Germany Peptic Ulcer Medication Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 228. Germany Peptic Ulcer Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 229. France Peptic Ulcer Medication Market Size, 2017-2032 (USD Million)
  • TABLE 230. France Peptic Ulcer Medication Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 231. France Peptic Ulcer Medication Market Size, by H2 Receptor Antagonists, 2017-2032 (USD Million)
  • TABLE 232. France Peptic Ulcer Medication Market Size, by Mucosal Protectants, 2017-2032 (USD Million)
  • TABLE 233. France Peptic Ulcer Medication Market Size, by Proton Pump Inhibitors, 2017-2032 (USD Million)
  • TABLE 234. France Peptic Ulcer Medication Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 235. France Peptic Ulcer Medication Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 236. France Peptic Ulcer Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 237. Russia Peptic Ulcer Medication Market Size, 2017-2032 (USD Million)
  • TABLE 238. Russia Peptic Ulcer Medication Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 239. Russia Peptic Ulcer Medication Market Size, by H2 Receptor Antagonists, 2017-2032 (USD Million)
  • TABLE 240. Russia Peptic Ulcer Medication Market Size, by Mucosal Protectants, 2017-2032 (USD Million)
  • TABLE 241. Russia Peptic Ulcer Medication Market Size, by Proton Pump Inhibitors, 2017-2032 (USD Million)
  • TABLE 242. Russia Peptic Ulcer Medication Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 243. Russia Peptic Ulcer Medication Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 244. Russia Peptic Ulcer Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 245. Italy Peptic Ulcer Medication Market Size, 2017-2032 (USD Million)
  • TABLE 246. Italy Peptic Ulcer Medication Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 247. Italy Peptic Ulcer Medication Market Size, by H2 Receptor Antagonists, 2017-2032 (USD Million)
  • TABLE 248. Italy Peptic Ulcer Medication Market Size, by Mucosal Protectants, 2017-2032 (USD Million)
  • TABLE 249. Italy Peptic Ulcer Medication Market Size, by Proton Pump Inhibitors, 2017-2032 (USD Million)
  • TABLE 250. Italy Peptic Ulcer Medication Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 251. Italy Peptic Ulcer Medication Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 252. Italy Peptic Ulcer Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 253. Spain Peptic Ulcer Medication Market Size, 2017-2032 (USD Million)
  • TABLE 254. Spain Peptic Ulcer Medication Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 255. Spain Peptic Ulcer Medication Market Size, by H2 Receptor Antagonists, 2017-2032 (USD Million)
  • TABLE 256. Spain Peptic Ulcer Medication Market Size, by Mucosal Protectants, 2017-2032 (USD Million)
  • TABLE 257. Spain Peptic Ulcer Medication Market Size, by Proton Pump Inhibitors, 2017-2032 (USD Million)
  • TABLE 258. Spain Peptic Ulcer Medication Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 259. Spain Peptic Ulcer Medication Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 260. Spain Peptic Ulcer Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 261. China Peptic Ulcer Medication Market Size, 2017-2032 (USD Million)
  • TABLE 262. China Peptic Ulcer Medication Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 263. China Peptic Ulcer Medication Market Size, by H2 Receptor Antagonists, 2017-2032 (USD Million)
  • TABLE 264. China Peptic Ulcer Medication Market Size, by Mucosal Protectants, 2017-2032 (USD Million)
  • TABLE 265. China Peptic Ulcer Medication Market Size, by Proton Pump Inhibitors, 2017-2032 (USD Million)
  • TABLE 266. China Peptic Ulcer Medication Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 267. China Peptic Ulcer Medication Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 268. China Peptic Ulcer Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 269. India Peptic Ulcer Medication Market Size, 2017-2032 (USD Million)
  • TABLE 270. India Peptic Ulcer Medication Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 271. India Peptic Ulcer Medication Market Size, by H2 Receptor Antagonists, 2017-2032 (USD Million)
  • TABLE 272. India Peptic Ulcer Medication Market Size, by Mucosal Protectants, 2017-2032 (USD Million)
  • TABLE 273. India Peptic Ulcer Medication Market Size, by Proton Pump Inhibitors, 2017-2032 (USD Million)
  • TABLE 274. India Peptic Ulcer Medication Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 275. India Peptic Ulcer Medication Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 276. India Peptic Ulcer Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 277. Japan Peptic Ulcer Medication Market Size, 2017-2032 (USD Million)
  • TABLE 278. Japan Peptic Ulcer Medication Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 279. Japan Peptic Ulcer Medication Market Size, by H2 Receptor Antagonists, 2017-2032 (USD Million)
  • TABLE 280. Japan Peptic Ulcer Medication Market Size, by Mucosal Protectants, 2017-2032 (USD Million)
  • TABLE 281. Japan Peptic Ulcer Medication Market Size, by Proton Pump Inhibitors, 2017-2032 (USD Million)
  • TABLE 282. Japan Peptic Ulcer Medication Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 283. Japan Peptic Ulcer Medication Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 284. Japan Peptic Ulcer Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 285. Australia Peptic Ulcer Medication Market Size, 2017-2032 (USD Million)
  • TABLE 286. Australia Peptic Ulcer Medication Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 287. Australia Peptic Ulcer Medication Market Size, by H2 Receptor Antagonists, 2017-2032 (USD Million)
  • TABLE 288. Australia Peptic Ulcer Medication Market Size, by Mucosal Protectants, 2017-2032 (USD Million)
  • TABLE 289. Australia Peptic Ulcer Medication Market Size, by Proton Pump Inhibitors, 2017-2032 (USD Million)
  • TABLE 290. Australia Peptic Ulcer Medication Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 291. Australia Peptic Ulcer Medication Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 292. Australia Peptic Ulcer Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 293. South Korea Peptic Ulcer Medication Market Size, 2017-2032 (USD Million)
  • TABLE 294. South Korea Peptic Ulcer Medication Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 295. South Korea Peptic Ulcer Medication Market Size, by H2 Receptor Antagonists, 2017-2032 (USD Million)
  • TABLE 296. South Korea Peptic Ulcer Medication Market Size, by Mucosal Protectants, 2017-2032 (USD Million)
  • TABLE 297. South Korea Peptic Ulcer Medication Market Size, by Proton Pump Inhibitors, 2017-2032 (USD Million)
  • TABLE 298. South Korea Peptic Ulcer Medication Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 299. South Korea Peptic Ulcer Medication Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 300. South Korea Peptic Ulcer Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 301. Global Peptic Ulcer Medication Market Share, by Key Player, 2025
  • TABLE 302. Global Peptic Ulcer Medication Market, Key Experts